MCID: HYP063
MIFTS: 49

Hypersplenism

Categories: Immune diseases, Blood diseases

Aliases & Classifications for Hypersplenism

MalaCards integrated aliases for Hypersplenism:

Name: Hypersplenism 12 55 44 15 73
Hypersplenia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6376
ICD10 33 D73.1
ICD9CM 35 289.4
MeSH 44 D006971
NCIt 50 C34714
UMLS 73 C0020532

Summaries for Hypersplenism

MalaCards based summary : Hypersplenism, also known as hypersplenia, is related to portal hypertension and portal vein thrombosis. An important gene associated with Hypersplenism is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Warfarin and Heparin have been mentioned in the context of this disorder. Affiliated tissues include spleen, liver and bone, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 76 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Related Diseases for Hypersplenism

Diseases related to Hypersplenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 portal hypertension 30.9 ALB F2 THPO
2 portal vein thrombosis 30.3 F2 SERPINC1
3 schistosomiasis 30.1 ALB F2 IFNG
4 esophageal varix 30.1 ALB F2 SERPINC1
5 hepatitis b 30.1 ALB F2 IFNG
6 liver cirrhosis 30.0 ALB F2 SERPINC1 THPO
7 endocarditis 29.9 ALB F2 SERPINC1
8 peripheral vascular disease 29.8 ALB F2 SERPINC1
9 purpura 29.7 F2 SERPINC1 THPO
10 malaria 28.9 ALB EPO FOXP3 IFNG
11 splenomegaly 11.3
12 nodular regenerative hyperplasia 10.9
13 antipyrine metabolism 10.8 ALB F2
14 non-a-e hepatitis 10.8 ALB F2
15 abdominal tuberculosis 10.8 ALB F2
16 kwashiorkor 10.8 ALB F2
17 hepatic tuberculosis 10.8 ALB F2
18 hepatic coma 10.8 ALB F2
19 calciphylaxis 10.7 ALB EPO
20 ascending cholangitis 10.7 ALB F2
21 gastrointestinal tuberculosis 10.7 ALB IFNG
22 spinal cord infarction 10.7 F2 SERPINC1
23 burns 10.7 ALB SERPINC1
24 intestinal impaction 10.7 F2 SERPINC1
25 sudden sensorineural hearing loss 10.7 F2 SERPINC1
26 blood protein disease 10.7 F2 SERPINC1
27 leech infestation 10.7 F2 SERPINC1
28 fetal erythroblastosis 10.7 ALB EPO
29 alpha-2-plasmin inhibitor deficiency 10.7 F2 SERPINC1
30 giant hemangioma 10.7 F2 SERPINC1
31 compartment syndrome 10.6 ALB F2
32 prothrombin deficiency, congenital 10.6 F2 SERPINC1
33 sagittal sinus thrombosis 10.6 F2 SERPINC1
34 chronic inflammatory demyelinating polyradiculoneuropathy 10.6 ALB IFNG
35 fascioliasis 10.6 ALB IFNG
36 blue toe syndrome 10.6 F2 SERPINC1
37 tuberculous peritonitis 10.6 ALB IFNG
38 intracranial embolism 10.6 F2 SERPINC1
39 ischemic colitis 10.6 F2 SERPINC1
40 choledocholithiasis 10.6 ALB F2
41 anterior spinal artery syndrome 10.6 F2 SERPINC1
42 subendocardial myocardial infarction 10.6 F2 SERPINC1
43 sneddon syndrome 10.6 F2 SERPINC1
44 retinal artery occlusion 10.6 F2 SERPINC1
45 rh isoimmunization 10.6 ALB EPO
46 marantic endocarditis 10.6 F2 SERPINC1
47 purpura fulminans 10.6 F2 SERPINC1
48 korean hemorrhagic fever 10.6 F2 SERPINC1
49 inherited blood coagulation disease 10.6 F2 SERPINC1
50 hepatic infarction 10.6 F2 SERPINC1

Comorbidity relations with Hypersplenism via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Iron Deficiency Anemia Neutropenia
Portal Hypertension Primary Thrombocytopenia

Graphical network of the top 20 diseases related to Hypersplenism:



Diseases related to Hypersplenism

Symptoms & Phenotypes for Hypersplenism

GenomeRNAi Phenotypes related to Hypersplenism according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 ALB IL2RA PIK3R1 SERPINC1 THPO

MGI Mouse Phenotypes related to Hypersplenism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 PIK3R1 FOXP3 SERPINC1 THPO IFNG EPO
2 homeostasis/metabolism MP:0005376 10.02 THPO F2 PIK3R1 FOXP3 SERPINC1 ALB
3 immune system MP:0005387 9.97 THPO PIK3R1 FOXP3 SERPINC1 IFNG EPO
4 digestive/alimentary MP:0005381 9.83 F2 FOXP3 ALB IFNG IL2RA
5 mortality/aging MP:0010768 9.76 F2 PIK3R1 FOXP3 SERPINC1 ALB IFNG
6 liver/biliary system MP:0005370 9.73 PIK3R1 FOXP3 SERPINC1 ALB IFNG EPO
7 normal MP:0002873 9.5 IL7R PIK3R1 FOXP3 ALB IFNG EPO
8 respiratory system MP:0005388 9.02 F2 FOXP3 IFNG IL2RA EPO

Drugs & Therapeutics for Hypersplenism

Drugs for Hypersplenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 6691 54678486
2
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4 Nadroparin Approved, Investigational Phase 4 9041-08-1
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
7
Dipyridamole Approved Phase 4 58-32-2 3108
8
Dalteparin Approved Phase 4 9005-49-6
9 tannic acid Approved, Nutraceutical Phase 4
10 Liver Extracts Phase 4,Phase 2,Phase 3,Not Applicable
11 Neurotransmitter Agents Phase 4,Phase 1,Phase 2
12 calcium heparin Phase 4
13 Analgesics Phase 4
14 Fibrinolytic Agents Phase 4
15 Adrenergic Agents Phase 4
16 Adrenergic alpha-1 Receptor Antagonists Phase 4
17 Adrenergic alpha-Antagonists Phase 4
18 Adrenergic Antagonists Phase 4
19 Adrenergic beta-Antagonists Phase 4,Not Applicable
20 Cyclooxygenase Inhibitors Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Heparin, Low-Molecular-Weight Phase 4
23 Vasodilator Agents Phase 4
24 Peripheral Nervous System Agents Phase 4
25 Phosphodiesterase Inhibitors Phase 4
26 Antihypertensive Agents Phase 4
27 Platelet Aggregation Inhibitors Phase 4
28 Anticoagulants Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Antipyretics Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Antirheumatic Agents Phase 4
33 Calcium, Dietary Phase 4
34
Valproic Acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
35
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
38
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
40 Staurosporine Experimental Phase 2 62996-74-1
41 4'-N-benzoylstaurosporine Phase 2
42 Central Nervous System Depressants Phase 1, Phase 2
43 GABA Agents Phase 1, Phase 2
44 Tranquilizing Agents Phase 1, Phase 2
45 Anticonvulsants Phase 1, Phase 2
46 Protein Kinase Inhibitors Phase 2
47 Psychotropic Drugs Phase 1, Phase 2
48 Antimanic Agents Phase 1, Phase 2
49 Micronutrients Phase 2
50 Nicotinic Acids Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Recruiting NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
2 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
3 ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis Unknown status NCT01560845 Phase 2, Phase 3
4 Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2 Valproic Acid
5 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Completed NCT00233454 Phase 2 Midostaurin
6 Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE Terminated NCT01539018 Phase 2 Sorafenib;sorafenib plus tegafur-uracil
7 Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584 Not Applicable
8 Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
9 Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection Completed NCT00825669 Not Applicable TACE
10 The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia Completed NCT00971698
11 The Treatment of Hepatocirrhosis and Portal Hypertension Recruiting NCT02778425 Not Applicable
12 Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) Recruiting NCT03469661
13 The Natural History and Prognostic Factors of Compensated Cirrhosis. Recruiting NCT03144700
14 Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension Not yet recruiting NCT03269877
15 Gall Bladder Status Among Children With Chronic Haemolytic Anemia Not yet recruiting NCT03533322

Search NIH Clinical Center for Hypersplenism

Cochrane evidence based reviews: hypersplenism

Genetic Tests for Hypersplenism

Anatomical Context for Hypersplenism

MalaCards organs/tissues related to Hypersplenism:

41
Spleen, Liver, Bone, Bone Marrow, T Cells, Myeloid, Testes

Publications for Hypersplenism

Articles related to Hypersplenism:

(show top 50) (show all 496)
# Title Authors Year
1
Use of Iodized Oil and Gelatin Sponge Embolization in Splenic Artery Coiling Reduces Bleeding from Laparoscopic Splenectomy for Cirrhotic Portal Hypertension Patients with Complicating Hypersplenic Splenomegaly: A Comparative Study. ( 29608435 )
2018
2
Epithelial cyst of spleen presenting as hypersplenism. ( 29386740 )
2018
3
Hypersplenism secondary to splenoportal axis compression by a giant hepatic cyst. ( 29019252 )
2018
4
Partial splenic embolization in the treatment of prolonged thrombocytopenia due to hypersplenism in metastatic cancer patients. ( 29696427 )
2018
5
Portal hypertension and hypersplenism in extrahepatic portal venous obstruction: Are they related? ( 29936618 )
2018
6
Incidence and risk factors associated with a high comprehensive complication index score after splenectomy in cirrhotic patients with hypersplenism. ( 29273377 )
2018
7
Laparoscopic splenectomy and subsequent oncologic gastric surgery in cirrhotic patients with portal hypertension and hypersplenism. ( 29391322 )
2018
8
Spleen Regulates Hematopoietic Stem/Progenitor Cell Functions Through Regulation of EGF in Cirrhotic Hypersplenism. ( 29721775 )
2018
9
JOURNAL CLUB: Four-Dimensional Flow MRI-Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism. ( 28463524 )
2017
10
Partial Splenic Artery Embolization to Treat Hypersplenism Secondary to Hepatic Cirrhosis: A Meta-Analysis. ( 28316312 )
2017
11
Successful Treatment of Hypersplenism in Wilson's Disease by Partial Splenic Embolization. ( 28135891 )
2017
12
Postoperative Prognostic Nutritional Index Predicts Survival of Patients with Hepatocellular Carcinoma within Milan Criteria and Hypersplenism. ( 28523484 )
2017
13
Klippel-Trenaunay-Weber syndrome with atypical presentation of hypersplenism and nephrotic syndrome: a case report. ( 28823249 )
2017
14
Airway management of a paediatric patient with temporomandibular joint ankylosis with extra hepatic portal vein obstruction, splenomegaly, hypersplenism, and obstructive sleep apnoea for shunt surgery: A unique challenge. ( 29217866 )
2017
15
Microwave ablation in the spleen versus partial splenic artery embolisation: A new technique for hypersplenism in cirrhosis. ( 28256406 )
2017
16
Hypersplenism Associated With Late-Presenting Congenital Diaphragmatic Hernia: A Rare Combination. Case Report. ( 27227931 )
2016
17
Severe hypersplenism associated to hemophagocytic and lymphoproliferative syndrome secondary to Epstein-Barr virus infection. A report of two cases. ( 27041246 )
2016
18
Laparoscopic splenic artery ligation for hypersplenism in cirrhosis: A case series. ( 27251809 )
2016
19
A Comparative Study of Surgical Splenectomy, Partial Splenic Embolization, and High-Intensity Focused Ultrasound for Hypersplenism. ( 26839374 )
2016
20
Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis. ( 26753954 )
2016
21
Partial Splenic Embolization in a Child with Sickle Cell Disease and Hypersplenism. ( 27926404 )
2016
22
Influence of lactulose on interventional therapy for HCC patients with hepatocirrhosis and hypersplenism. ( 26919955 )
2016
23
Invasive group B streptococcal infection in a patient with post splenectomy for hypersplenism secondary to liver cirrhosis and portal hypertension. ( 27006743 )
2016
24
Simultaneous microwave coagulo-necrotic therapy (MCN) and laparoscopic splenectomy for the treatment of hepatocellular carcinoma with cirrhotic hypersplenism. ( 27577937 )
2016
25
Hypersplenism: History and current status. ( 27703501 )
2016
26
Risk Factors for Portal Vein System Thrombosis After Laparoscopic Splenectomy in Cirrhotic Patients with Hypersplenism. ( 26953863 )
2016
27
Laparoscopic versus traditional open splenectomy for hepatocellular carcinoma with hypersplenism. ( 27465326 )
2016
28
Hepatocellular Carcinoma with Hypersplenic Thrombocytopenia and Situs Inversus Totalis: A Case Report. ( 28031104 )
2016
29
Dameshek W, Miller EB. The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism. 1946. ( 26744432 )
2016
30
Treatment of Hypersplenism by Partial Splenic Embolization Through Gastric Collaterals. ( 27200164 )
2016
31
Laparoscopic Splenectomy for the Elderly Liver Cirrhotic Patients With Hypersplenism: A Retrospective Comparable Study. ( 26962816 )
2016
32
Effect of partial splenic embolization on the immune function of cirrhosis patients with hypersplenism. ( 27393102 )
2016
33
Pancreatic fistula after laparoscopic splenectomy in patients with hypersplenism due to liver cirrhosis: effect of fibrin glue and polyglycolic acid felt on prophylaxis of postoperative complications. ( 27162072 )
2016
34
Hypersplenism in liver disease and SLE revisited: current evidence supports an active rather than passive process. ( 26865982 )
2016
35
Comparison of two laparoscopic splenectomy plus pericardial devascularization techniques for management of portal hypertension and hypersplenism. ( 25783835 )
2015
36
Partial splenic embolization of patients with hypersplenism by transradial or transfemoral approach: a prospective randomized controlled trial. ( 26671306 )
2015
37
Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis. ( 26316782 )
2015
38
Partial Splenic Artery Embolization for the Management of Hypersplenism in Cirrhosis. ( 26388645 )
2015
39
Percutaneous Microwave Ablation in the Spleen for Treatment of Hypersplenism in Cirrhosis Patients. ( 26031423 )
2015
40
Radiofrequency ablation for treatment of hypersplenism: A feasible therapeutic option. ( 26034376 )
2015
41
An innovative modification of sandwich embolization technique for simultaneous management of ruptured pseudoaneurysm of branch of splenic artery and hypersplenism syndrome. ( 25900542 )
2015
42
Hypersplenism Treated by Partial Splenic Embolization Using Guglielmi Detachable Coils. ( 26328643 )
2015
43
Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6C(lo) macrophages. ( 26022691 )
2015
44
Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study. ( 25741142 )
2015
45
Laparoscopic splenic vessels ligation as a treatment of hypersplenism and thrombocytopenia in children. ( 26659241 )
2015
46
Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China. ( 25910248 )
2015
47
Hypersplenism: an independent risk factor for myocardial remodeling in chronic heart failure patients. ( 26131093 )
2015
48
Anaesthetic management of beta thalassemia major with hypersplenism for splenectomy in pediatric age group: Report of four cases. ( 26417142 )
2015
49
Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers? ( 25788189 )
2015
50
Portal and splanchnic hemodynamics after partialA splenic embolization in cirrhotic patients with hypersplenism. ( 26547369 )
2015

Variations for Hypersplenism

Expression for Hypersplenism

Search GEO for disease gene expression data for Hypersplenism.

Pathways for Hypersplenism

Pathways related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.42 EPO F2 IFNG IL2RA IL7R PIK3R1
2
Show member pathways
13.15 EPO F2 IFNG IL2RA IL7R PIK3R1
3
Show member pathways
13.03 ALB F2 IL2RA PIK3R1 SERPINC1 THPO
4
Show member pathways
12.76 EPO IL2RA IL7R PIK3R1
5
Show member pathways
12.67 IL2RA IL7R PIK3R1 THPO
6 12.58 EPO IFNG IL2RA IL7R PIK3R1
7
Show member pathways
12.12 ALB F2 IFNG
8
Show member pathways
12.03 EPO IFNG IL2RA IL7R PIK3R1 THPO
9 11.95 IL2RA IL7R PIK3R1
10
Show member pathways
11.86 IFNG IL2RA PIK3R1
11
Show member pathways
11.73 IFNG IL2RA IL7R PIK3R1 THPO
12 11.72 EPO IFNG PIK3R1
13 11.6 IFNG IL2RA IL7R
14
Show member pathways
11.57 FOXP3 IFNG IL2RA
15 11.54 EPO IL2RA IL7R THPO
16
Show member pathways
11.5 FOXP3 IL2RA PIK3R1
17 11.5 EPO IFNG IL2RA IL7R PIK3R1
18
Show member pathways
11.27 IL2RA IL7R PIK3R1
19 11.24 FOXP3 IFNG IL2RA
20 11.14 IFNG IL2RA
21 11.09 EPO IFNG IL2RA IL7R THPO
22
Show member pathways
11.07 IFNG IL2RA
23 11.04 IFNG IL2RA
24 11.03 IL7R PIK3R1
25 10.97 F2 IFNG
26 10.91 IFNG PIK3R1

GO Terms for Hypersplenism

Cellular components related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 ALB EPO F2 IFNG SERPINC1 THPO
2 blood microparticle GO:0072562 9.33 ALB F2 SERPINC1
3 extracellular region GO:0005576 9.17 ALB EPO F2 IFNG IL7R SERPINC1

Biological processes related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.73 EPO F2 IFNG IL7R
2 cellular protein metabolic process GO:0044267 9.69 ALB F2 SERPINC1
3 regulation of signaling receptor activity GO:0010469 9.67 EPO F2 IFNG THPO
4 positive regulation of protein phosphorylation GO:0001934 9.58 F2 IFNG THPO
5 negative regulation of T cell proliferation GO:0042130 9.54 FOXP3 IL2RA
6 acute-phase response GO:0006953 9.52 EPO F2
7 T cell homeostasis GO:0043029 9.49 FOXP3 IL2RA
8 negative regulation of immune response GO:0050777 9.48 FOXP3 IL2RA
9 positive regulation of activated T cell proliferation GO:0042104 9.46 EPO IL2RA
10 cell surface receptor signaling pathway GO:0007166 9.46 F2 IFNG IL2RA IL7R
11 regulation of blood coagulation GO:0030193 9.32 F2 SERPINC1
12 negative regulation of interleukin-17 production GO:0032700 9.26 FOXP3 IFNG
13 negative regulation of lymphocyte proliferation GO:0050672 8.96 FOXP3 IL2RA
14 regulation of regulatory T cell differentiation GO:0045589 8.8 FOXP3 IFNG IL2RA

Molecular functions related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 EPO IFNG THPO

Sources for Hypersplenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....